세계의 구강암 치료 시장 성장 기회와 산업 예측(2021-2030년) : 약제 종류별, 연령층별, 최종사용자별

The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.

Oral cancer is a type of head and neck cancer that manifests itself in the mouth as a tumor. The tongue, lips, cheeks, gums, tonsils, and salivary glands are the most common sites for oral or mouth cancer. Oral cancers are classified as either benign or malignant. Surgical removal of benign tumors is possible. Squamous cell carcinoma accounts for 90% of malignant oral malignancies, which can spread to other parts of the body. Furthermore, according to the Oral Cancer Foundation, every year around 53,000 new oral cancer cases are diagnosed and more than 9,750 people succumb to the disease in the U.S. Oral cancer accounts for 4% of total cancer cases and causes 2.2% deaths in the U.S. In western countries, prevalence of oral cancer is 2% to 6% of the total cancer cases. In addition, in Asia-Pacific, the oropharyngeal cancer is more common among men than women. According to the National Cancer Institute, 60% of people with oral cancer survive for five years or more and 70% to 90% of people with Stage 1 or 2 cancer survive for more than 5 years.

The growth of the global oral cancer treatment market is majorly driven by rise in prevalence of oral or mouth cancer globally is a major factor fostering the growth of the market. Rise in expenditure on the development of healthcare infrastructure, increase in consumption of tobacco products such as cigarettes, cigars, pipes and chewing tobacco and upsurge in the special designation from regulatory authorities are other factors also fostering the growth of the market. Increase in personal disposable income coupled with rise in prevalence of papillomavirus infection is other indirect determinant that will create lucrative market growth opportunities.

However, lack of awareness about the oral cancer in the backward and underdeveloped areas will hamper the market growth. Risk of recurrence even after the treatment will also hamper the market growth rate.

The oral cancer treatment market is segmented on the basis of treatment, age group, end user, and region. Depending on treatment, the market is classified into chemotherapy, immunotherapy, targeted therapy. The age group segment is further categorized into 30-49, 50-69 and 70<. By end user, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, online stores. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the global oral cancer treatment market along with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps understand the applications and products of oral injury used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

• By Treatment
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• By Age Group
• 30-49
• 50-69
• 70<
• By End User
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Stores
• By Region
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key benefits for stakeholders
• 1.3.Key market segments
  • 1.3.1.List of key players profiled in the report
• 1.4.Research methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
  • 3.2.2.Top winning strategies
• 3.3.Porter's five force analysis
• 3.4.Top player positioning, 2020
• 3.5.Market dynamics
  • 3.5.1.Drivers
    • 3.5.1.1.Rise in prevalence of oral cancer
    • 3.5.1.2.Surge in global geriatric population
    • 3.5.1.3.Increase in government expenditure on healthcare
  • 3.5.2.Restraint
    • 3.5.2.1.Adverse effects associated with the use cancer drugs
  • 3.5.3.Opportunities
    • 3.5.3.1.High growth potential in untapped emerging economies
    • 3.5.3.2.Increase in number of pipeline drugs
  • 3.5.4.Impact analysis
• 3.6.COVID-19 impact analysis on the oral cancer treatment market

CHAPTER 4:ORAL CANCER TREATMENT MARKET, BY DRUG TYPE

• 4.1.Overview
  • 4.1.1.Market size and forecast
• 4.2.Chemotherapy
  • 4.2.1.Key market trends, growth factors, and opportunities
  • 4.2.2.Market size and forecast, by region
  • 4.2.3.Market analysis, by country
• 4.3.Immunotherapy
  • 4.3.1.Key market trends, growth factors, and opportunities
  • 4.3.2.Market size and forecast, by region
  • 4.3.3.Market analysis, by country
• 4.4.Targeted therapy
  • 4.4.1.Key market trends, growth factors, and opportunities
  • 4.4.2.Market size and forecast, by region
  • 4.4.3.Market analysis, by country

CHAPTER 5:ORAL CANCER TREATMENT MARKET, BY AGE GROUP

• 5.1.Overview
  • 5.1.1.Market size and forecast
• 5.2.30-49
  • 5.2.1.Market size and forecast, by region
  • 5.2.2.Market analysis, by country
• 5.3.50-69
  • 5.3.1.Market size and forecast, by region
  • 5.3.2.Market analysis, by country
• 5.4.70<
  • 5.4.1.Market size and forecast, by region
  • 5.4.2.Market analysis, by country

CHAPTER 6:ORAL CANCER TREATMENT MARKET, BY END USER

• 6.1.Overview
  • 6.1.1.Market size and forecast
• 6.2.Hospital Pharmacies
  • 6.2.1.Market size and forecast, by region
  • 6.2.2.Market analysis, by country
• 6.3.Drug Stores & Retail Pharmacies
  • 6.3.1.Market size and forecast, by region
  • 6.3.2.Market analysis, by country
• 6.4.Online Stores
  • 6.4.1.Market size and forecast, by region
  • 6.4.2.Market analysis, by country

CHAPTER 7:ORAL CANCER TREATMENT MARKET, BY REGION

• 7.1.Overview
  • 7.1.1.Market size and forecast
• 7.2.North America
  • 7.2.1.Key market trends, growth factors, and opportunities
  • 7.2.2.Market size and forecast, by country
    • 7.2.2.1.U.S. oral cancer treatment market, by drug type
    • 7.2.2.2.U.S. oral cancer treatment market, by age group
    • 7.2.2.3.U.S. oral cancer treatment market, by distribution channel
    • 7.2.2.4.Canada oral cancer treatment market, by drug type
    • 7.2.2.5.Canada oral cancer treatment market, by age group
    • 7.2.2.6.Canada oral cancer treatment market, by distribution channel
    • 7.2.2.7.Mexico oral cancer treatment market, by drug type
    • 7.2.2.8.Mexico oral cancer treatment market, by age group
    • 7.2.2.9.Mexico oral cancer treatment market, by distribution channel
• 7.3.Europe
  • 7.3.1.Key market trends, growth factors, and opportunities
  • 7.3.2.Market size and forecast, by country
    • 7.3.2.1.Germany oral cancer treatment market, by drug type
    • 7.3.2.2.Germany oral cancer treatment market, by age group
    • 7.3.2.3.Germany oral cancer treatment market, by distribution channel
    • 7.3.2.4.France oral cancer treatment market, by drug type
    • 7.3.2.5.France oral cancer treatment market, by age group
    • 7.3.2.6.France oral cancer treatment market, by distribution channel
    • 7.3.2.7.UK oral cancer treatment market, by drug type
    • 7.3.2.8.UK oral cancer treatment market, by age group
    • 7.3.2.9.UK oral cancer treatment market, by distribution channel
    • 7.3.2.10.Italy oral cancer treatment market, by drug type
    • 7.3.2.11.Italy oral cancer treatment market, by age group
    • 7.3.2.12.Italy oral cancer treatment market, by distribution channel
    • 7.3.2.13.Spain oral cancer treatment market, by drug type
    • 7.3.2.14.Spain oral cancer treatment market, by age group
    • 7.3.2.15.Spain oral cancer treatment market, by distribution channel
    • 7.3.2.16.Rest of Europe oral cancer treatment market, by drug type
    • 7.3.2.17.Rest of Europe oral cancer treatment market, by age group
    • 7.3.2.18.Rest of Europe oral cancer treatment market, by distribution channel
  • 7.3.3.Europe oral cancer treatment market, by drug type
  • 7.3.4.Europe oral cancer treatment market, by age group
  • 7.3.5.Europe oral cancer treatment market, by distribution channel
• 7.4.Asia-Pacific
  • 7.4.1.Key market trends, growth factors, and opportunities
  • 7.4.2.Market size and forecast, by country
    • 7.4.2.1.Japan oral cancer treatment market, by drug type
    • 7.4.2.2.Japan oral cancer treatment market, by age group
    • 7.4.2.3.Japan oral cancer treatment market, by distribution channel
    • 7.4.2.4.China oral cancer treatment market, by drug type
    • 7.4.2.5.China oral cancer treatment market, by age group
    • 7.4.2.6.China oral cancer treatment market, by distribution channel
    • 7.4.2.7.Australia oral cancer treatment market, by drug type
    • 7.4.2.8.Australia oral cancer treatment market, by age group
    • 7.4.2.9.Australia oral cancer treatment market, by distribution channel
    • 7.4.2.10.India oral cancer treatment market, by drug type
    • 7.4.2.11.India oral cancer treatment market, by age group
    • 7.4.2.12.India oral cancer treatment market, by distribution channel
    • 7.4.2.13.South Korea oral cancer treatment market, by drug type
    • 7.4.2.14.South Korea oral cancer treatment market, by age group
    • 7.4.2.15.South Korea oral cancer treatment market, by distribution channel
    • 7.4.2.16.Rest of Asia-Pacific oral cancer treatment market, by drug type
    • 7.4.2.17.Rest of Asia-Pacific oral cancer treatment market, by age group
    • 7.4.2.18.Rest of Asia-Pacific oral cancer treatment market, by distribution channel
  • 7.4.3.Asia-Pacific oral cancer treatment market, by drug type
  • 7.4.4.Asia-Pacific oral cancer treatment market, by age group
  • 7.4.5.Asia-Pacific oral cancer treatment market, by distribution channel
• 7.5.LAMEA
  • 7.5.1.Key market trends, growth factors, and opportunities
  • 7.5.2.Market size and forecast, by country
    • 7.5.2.1.Brazil oral cancer treatment market, by drug type
    • 7.5.2.2.Brazil oral cancer treatment market, by age group
    • 7.5.2.3.Brazil oral cancer treatment market, by distribution channel
    • 7.5.2.4.Saudi Arabia oral cancer treatment market, by drug type
    • 7.5.2.5.Saudi Arabia oral cancer treatment market, by age group
    • 7.5.2.6.Saudi Arabia oral cancer treatment market, by distribution channel
    • 7.5.2.7.South Africa oral cancer treatment market, by drug type
    • 7.5.2.8.South Africa oral cancer treatment market, by age group
    • 7.5.2.9.South Africa oral cancer treatment market, by distribution channel
    • 7.5.2.10.Rest of LAMEA oral cancer treatment market, by drug type
    • 7.5.2.11.Rest of LAMEA oral cancer treatment market, by age group
    • 7.5.2.12.Rest of LAMEA oral cancer treatment market, by distribution channel
  • 7.5.3.LAMEA oral cancer treatment market, by drug type
  • 7.5.4.LAMEA oral cancer treatment market, by age group
  • 7.5.5.LAMEA oral cancer treatment market, by distribution channel

CHAPTER 8:COMPANY PROFILES

• 8.1.BRISTOL MAYERS SQUIBB COMPANY
  • 8.1.1.Company overview
  • 8.1.2.Company snapshot
  • 8.1.3.Operating business segments
  • 8.1.4.Product portfolio
  • 8.1.5.Business performance
  • 8.1.6.Key strategic moves and developments
• 8.2.CIPLA INC.
  • 8.2.1.Company overview
  • 8.2.2.Company snapshot
  • 8.2.3.Operating business segments
  • 8.2.4.Product portfolio
  • 8.2.5.Business performance
  • 8.2.6.Key strategic moves and developments
• 8.3.ELI-LILLY
  • 8.3.1.Company overview
  • 8.3.2.Company snapshot
  • 8.3.3.Operating business segments
  • 8.3.4.Product portfolio
  • 8.3.5.Business performance
• 8.4.F-HOFFMANN-LA-ROCHE
  • 8.4.1.Company overview
  • 8.4.2.Company snapshot
  • 8.4.3.Operating business segments
  • 8.4.4.Product portfolio
  • 8.4.5.Business performance
  • 8.4.6.Key strategic moves and developments
• 8.5.FRESENIUS KABI AG
  • 8.5.1.Company overview
  • 8.5.2.Company snapshot
  • 8.5.3.Operating business segments
  • 8.5.4.Product portfolio
  • 8.5.5.Business performance
• 8.6.INTAS PHARMACEUTICALS LTD.
  • 8.6.1.Company overview
  • 8.6.2.Company snapshot
  • 8.6.3.Product portfolio
• 8.7.MERCK & CO. INC.
  • 8.7.1.Company overview
  • 8.7.2.Company snapshot
  • 8.7.3.Operating business segments
  • 8.7.4.Product portfolio
  • 8.7.5.Business performance
  • 8.7.6.Key strategic moves and developments
• 8.8.SANOFI S.A
  • 8.8.1.Company overview
  • 8.8.2.Company snapshot
  • 8.8.3.Operating business segments
  • 8.8.4.Product portfolio
  • 8.8.5.Business performance
  • 8.8.6.Key strategic moves and developments
• 8.9.TEVA PHARMACEUTICALS INDUSTRIES LTD
  • 8.9.1.Company overview
  • 8.9.2.Company snapshot
  • 8.9.3.Operating business segments
  • 8.9.4.Product Portfolio
  • 8.9.5.Business performance
• 8.10.VIATRIS INC. (MYLAN N.V)
  • 8.10.1.Company overview
  • 8.10.2.Company snapshot
  • 8.10.3.Operating business segments
  • 8.10.4.Product Portfolio
  • 8.10.5.Business performance